Loading...
•
Apr 30, 2021
Cooper Q2 2021 Earnings Report
CooperCompanies reported record quarterly earnings driven by strong performance in both CooperVision and CooperSurgical.
Key Takeaways
CooperCompanies announced strong second-quarter results with revenue up 37% year-over-year to $719.5 million. Both CooperVision and CooperSurgical posted all-time record quarterly revenues, driving record quarterly earnings. The company has updated its fiscal year 2021 financial guidance.
Revenue increased 37% year-over-year to $719.5 million.
CooperVision revenue was up 30% to $522.6 million.
CooperSurgical revenue was up 60% to $196.9 million.
Non-GAAP diluted earnings per share were $3.38, up 123% from last year's second quarter.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Office & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The company has updated its fiscal year 2021 financial guidance.
Positive Outlook
- Fiscal 2021 total revenue $2,855 - $2,885 million (14% to 15% constant currency)
- CVI revenue $2,110 - $2,130 million (11% to 12% constant currency)
- CSI revenue $745 - $755 million (25% to 27% constant currency)
- Fiscal 2021 non-GAAP diluted EPS $13.20 - $13.40
Challenges Ahead
- Resurgences of COVID-19 are viewed as a significant risk factor to the outlook.
- Inherent difficulty in forecasting acquisition-related, integration and restructuring charges and expenses.
- Unknown effect, timing and potential significance of such charges and expenses that impact GAAP diluted earnings per share.
- Adverse changes in the global or regional general business, political and economic conditions
- Foreign currency exchange rate and interest rate fluctuations
Revenue & Expenses
Visualization of income flow from segment revenue to net income